07:36 ET MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

prnewswire
2025.12.11 12:38
portai
I'm PortAI, I can summarize articles.

The Schall Law Firm has announced a class action lawsuit against MoonLake Immunotherapeutics for securities fraud, alleging false and misleading statements about its drug candidate, sonelokimab. Investors who purchased shares between March 10, 2024, and September 29, 2025, are encouraged to join the lawsuit by December 15, 2025. The lawsuit claims MoonLake's public statements were misleading, leading to significant investor losses.